Evidence map›Paper›PMID 42573624›Full record

ArticleJournal of gastroenterology2026

rs57494551 increases CXCR5 expression and IgM

Yuki Hitomi, Yoshihiro Aiba, Kazuko Ueno, Haruka Takahashi, Michihiro Kono, Kazuhiro Sugi, Yuji Teraoka, Shintaro Takaki, Atsushi Naganuma, Motoyuki Kojima and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yuki HitomiDepartment of Biometry and Genetics, Institute of Biomedical Sciences, Fukushima Medical University School of Medicine, 1 Hikariga-oka, Fukushima city, Fukushima, 960-1295, Japan. yhitomi@fmu.ac.jp.ORCID http://orcid.org/0000-0002-6713-7875
Yoshihiro AibaClinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Omura, Japan.
Kazuko UenoGenome Medical Science Project, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Haruka TakahashiLaboratory for Human Immunogenetics, Riken Center for Integrative Medical Sciences, Yokohama, Japan.
Michihiro KonoLaboratory for Human Immunogenetics, Riken Center for Integrative Medical Sciences, Yokohama, Japan.
Kazuhiro SugiDepartment of Gastroenterology and Hepatology, National Hospital Organization (NHO) Kumamoto Medical Center, Kumamoto, Japan.
Yuji TeraokaDepartment of Gastroenterology, National Hospital Organization (NHO) Kure Medical and Chugoku Cancer Center, Kure, Japan.
Shintaro TakakiDepartment of Gastroenterology, National Hospital Organization (NHO) Kure Medical and Chugoku Cancer Center, Kure, Japan.
Atsushi NaganumaDepartment of Gastroenterology, National Hospital Organization (NHO) Takasaki General Medical Center, Takasaki, Japan.
Motoyuki KojimaDepartment of Gastroenterology, National Hospital Organization (NHO) Kyushu Medical Center, Fukuoka, Japan.
Nao NishidaDepartment of Genomic Function and Diversity, Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan.
Yosuke KawaiGenome Medical Science Project, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Minae KawashimaDatabase Center for Life Science, Research Organization of Information and Systems, Kashiwa, Japan.
Seik-Soon KhorGenome Medical Science Project, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Michio YasunamiMedical Research Institute, Saga-Ken Medical Centre Koseikan, Saga, Japan.
Atsumasa KomoriClinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Omura, Japan.
Shinji ShimodaDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Kazuyoshi IshigakiLaboratory for Human Immunogenetics, Riken Center for Integrative Medical Sciences, Yokohama, Japan.
Masao NagasakiDivision of Biomedical Information Analysis, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
Katsushi TokunagaGenome Medical Science Project, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Minoru NakamuraClinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Omura, Japan.

Funding

Japan Agency for Medical Research and Development 19km0405205h9904Japan Agency for Medical Research and Development JP20ek0109485Japan Agency for Medical Research and Development JP20ek0109492Japan Agency for Medical Research and Development JP21ek0109548Japan Agency for Medical Research and Development JP21wm0425009Japan Agency for Medical Research and Development JP22ek0410099Japan Agency for Medical Research and Development JP22tm0424223Japan Agency for Medical Research and Development JP23ek0109617Japan Agency for Medical Research and Development JP23ek0109672Japan Agency for Medical Research and Development JP23ek0109675Japan Agency for Medical Research and Development JP23ek0210194Japan Agency for Medical Research and Development JP23tm0524005Japan Science and Technology Agency JPMJND2302Japan Society for the Promotion of Science 17H04169Japan Society for the Promotion of Science 19K08413Japan Society for the Promotion of Science 20K08370Japan Society for the Promotion of Science 22H03114Japan Society for the Promotion of Science 22K08065Japan Society for the Promotion of Science 23K07366Japan Society for the Promotion of Science 23K07471Japan Society for the Promotion of Science JP21H02681National Center for Global Health and Medicine 23A1007
6 · The paper itself

Abstract

backgroundPrimary biliary cholangitis (PBC) is a chronic, progressive, cholestatic liver disease caused by autoimmune reactions. A previous international meta-analysis of a genome-wide association study (GWAS) reported a robust association of the human chr.11q23.3 locus including C-X-C motif chemokine receptor 5 (CXCR5) with susceptibility to PBC. However, the molecular mechanism by which CXCR5 confers disease susceptibility in PBC remains unclear.

methodsCutting-edge post-GWAS analyses were conducted using in silico and in vitro functional approaches, including multi-omics analysis, machine-learning-based transcription factor prediction, and prime editor as a genome-editing technology. Expression data for CXCR5 and correlated genes were obtained by RNA-seq and immunohistochemistry analyses.

resultsAmong the variants around CXCR5, rs57494551 was identified as a disease-causal variant for PBC. rs57494551 regulates endogenous CXCR5 expression in B-cells through binding to the transcription repressor TEA domain transcription factor 3 (TEAD3). CXCR5 expression was correlated with disease activity, as identified by hierarchical clustering of mRNA expression patterns, and portal inflammation markers, such as serum IgM, Aspartate Transferase (AST), and Mac-2 binding protein glycosylation isomer (M2BPGi). The number of IgM

conclusionsImmune dysregulation and portal inflammation are affected by increased expression of CXCR5 on IgM HIGHLIGHTS: Among hundreds of genetic variants in CXCR5, rs57494551 was identified as a disease-causal variant using cutting-edge post-GWAS in silico and in vitro analyses, including multi-omics analysis, machine learning-based prediction, and the genome-editing technology "Prime Editor." The disease risk allele of rs57494551 increases endogenous CXCR5 expression in B-cells by releasing the binding of the transcriptional repressor TEAD3. RNA-seq and immunohistochemistry analyses revealed that CXCR5 expression is correlated with disease activity and portal inflammation markers. Furthermore, the number of IgM+ CXCR5+ B-cells was increased in the portal area of PBC with high disease activity. As well as PBC, the signifi cant associations between CXCR5 and susceptibility to various autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, systemic sclerosis, celiac disease, and Sjögren's syndrome, could be explained by the effect of rs57494551.

Indexed as

Genome editingGenome-wide association study (GWAS)ImmunohistochemistryPrimary biliary cholangitisTranscriptome analysis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.